Use of a Next Generation Sequencing (NGS) Panel to Determine Related Donor Eligibility in a Case of Pediatric Myelodysplastic Syndrome (MDS)

For patients with myeloid malignancies (e.g. MDS, myeloproliferative neoplasms (MPN), and acute myelogenous leukemia (AML)), application of next-generation sequencing (NGS) panels is usually limited to diagnosis, prognosis, and development of personalized treatment strategies (i.e., targeted therapies). Here we present a case in which results from an NGS panel were used to determine sibling eligibility for hematopoietic stem cell transplant in a 17 year old male with MDS. Library preparation was performed with DNA extracted from the peripheral blood of both the patients, and an 11 year old female sibling, using Illumina's TruSeq Custom Amplicon Technology.
Source: Cancer Genetics and Cytogenetics - Category: Genetics & Stem Cells Authors: Source Type: research